Lesén Eva, Granfeldt Daniel, Houchard Aude, Berthon Anthony, Dinet Jérôme, Gabriel Sylvie, Björstad Åse, Björholt Ingela, Elf Anna-Karin, Johanson Viktor
Nordic Health Economics, Gothenburg, Sweden.
PharmaLex Sweden, formerly Nordic Health Economics, Gothenburg, Sweden.
Eur J Cancer Care (Engl). 2019 Mar;28(2):e12983. doi: 10.1111/ecc.12983. Epub 2019 Jan 16.
The objective was to estimate the cost-of-illness of grades 1 and 2 metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in Sweden in 2013 in a population-based study including all patients diagnosed between 2005 and 2013. Data were obtained from national registers, and patients who utilised healthcare resources due to metastatic GEP-NETs in 2013 were included. The study included 478 patients (mean age 64 [SD=11] years, 51% men). The majority (80%) had small intestinal NET, 10% had pancreatic NET, and 41% had carcinoid syndrome. The total cost-of-illness was €12,189,000 in 2013, of which direct costs constituted 77% and costs from production loss constituted 22%. The largest contributor to the direct medical costs was prescription drugs (54%; primarily somatostatin analogues [91% of the total drug cost]). Production loss due to sickness absence constituted 52% of the total costs of production loss. The total annual cost per patient was €25,500. By patient group, the cost was €24,800 (95% CI €21,600-€28,100) for patients with small intestinal NET, €37,300 (95% CI €23,300-€51,300) for those with pancreatic NET and €18,600 (95% CI €12,600-€24,500) for patients with other GEP-NETs. To conclude, the total annual cost of grades 1 and 2 metastatic GEP-NETs in Sweden was €25,500 per patient and year.
目的是在一项基于人群的研究中，估算2013年瑞典1级和2级转移性胃肠胰神经内分泌肿瘤（GEP-NETs）的疾病成本，该研究纳入了2005年至2013年期间确诊的所有患者。数据来自国家登记处，纳入了2013年因转移性GEP-NETs而使用医疗资源的患者。该研究包括478名患者（平均年龄64岁[标准差=11]，51%为男性）。大多数患者（80%）患有小肠神经内分泌肿瘤，10%患有胰腺神经内分泌肿瘤，41%患有类癌综合征。2013年疾病总成本为1218.9万欧元，其中直接成本占77%，生产损失成本占22%。直接医疗成本的最大贡献者是处方药（54%；主要是生长抑素类似物[占总药物成本的91%]）。因病缺勤导致的生产损失占生产损失总成本的52%。每位患者的年度总成本为25500欧元。按患者组划分，小肠神经内分泌肿瘤患者的成本为24800欧元（95%置信区间21600-28100欧元），胰腺神经内分泌肿瘤患者为37300欧元（95%置信区间23300-51300欧元），其他GEP-NETs患者为18600欧元（95%置信区间12600-24500欧元）。总之，瑞典1级和2级转移性GEP-NETs的年度总成本为每位患者每年25500欧元。
